NCT01518036

Use of Somatropin in Turner Syndrome

The Use of Norditropin® in Turner's Syndrome

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 57 (actual)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: Female
• Age: 2 Years – 11 Years
• Healthy volunteers: Not accepted

Summary

This trial is conducted in Europe. The aim of this trial is to study the dose-response relationship and effect of somatropin (Norditropin®) on final height in girls with Turner Syndrome.

Conditions

• Genetic Disorder
• Turner Syndrome

Interventions

Type	Name	Description
DRUG	somatropin	2.9 IU/m\^2/day. Administered as once daily subcutaneous injection until final height is reached
DRUG	somatropin	4.3 IU/m\^2/day. Administered as once daily subcutaneous injection until final height is reached

Timeline

• Start date: 1987-09-14
• Primary completion: 2004-04-11
• Completion: 2004-04-11
• First posted: 2012-01-25
• Last updated: 2017-02-28

Locations

1 site across 1 country: United Kingdom